Novanta Discloses Riverpoint Medical Financials: $1.45B Deal, $250M Milestone Due January 2027
NOVT sits 52% above its 52-week low of $98.27.
Summary
Novanta filed required financial statements for its $1.45 billion Riverpoint Medical acquisition, revealing a $250 million milestone payment due January 2027 and preliminary purchase price allocation of $726 million in intangibles and $819 million in goodwill.
Key Events · M&A and Partnerships · NOVT
-
Final Purchase Price: $1.45 Billion
Total consideration of $1,450.6 million includes $1,206.5 million cash paid at closing plus a $250 million milestone payment due on or before January 8, 2027, recorded at fair value of $244.1 million.
-
Purchase Price Allocation
Preliminary allocation assigns $726.0 million to identifiable intangible assets (customer relationships $540M, developed technology $170M, trade name $16M) and $819.1 million to goodwill.
-
Runway Buyer Financials
FY2025: revenue $136.1M, net income $11.5M. Q1 2026: revenue $33.5M, net income $2.4M. Two customers accounted for 30% of FY2025 sales.
-
Pro Forma Combined Results
Q1 2026 pro forma revenue $291.2M, net income $9.6M. FY2025 pro forma revenue $1,116.7M, net loss $7.4M driven by $45.7M incremental intangible amortization and $28.7M new debt interest.
Analysis · NOVT · Manufacturing
This 8-K/A completes the required financial disclosures for Novanta's $1.45 billion acquisition of Riverpoint Medical, which closed on July 23, 2026. The filing reveals that the final purchase price is $250 million higher than the previously reported $1.2 billion, driven by a milestone payment due January 8, 2027. Runway Buyer generated $136.1 million in revenue and $11.5 million in net income in FY2025, with Q1 2026 revenue of $33.5 million. The pro forma combined company shows Q1 2026 revenue of $291.2 million and net income of $9.6 million, but a FY2025 pro forma net loss of $7.4 million due to $45.7 million in incremental intangible amortization and $28.7 million in new debt interest. The purchase price allocation assigns $726 million to identifiable intangibles and $819 million to goodwill, meaning significant future amortization expense will pressure reported earnings.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NOVT was trading at $149.27 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $98.27 to $176.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.